Amlodipine 5mg is an appropriate starting dose for newly diagnosed hypertension, but it is NOT the first-line choice according to current guidelines.
For non-Black patients, start with a low-dose ACE inhibitor or ARB first, not amlodipine. For Black patients, amlodipine (a DHP-CCB) is an appropriate first-line option, typically combined with an ARB or thiazide diuretic 1.
Patient Race/Ethnicity Determines First-Line Therapy
The 2020 ISH guidelines provide clear algorithmic guidance based on race:
Non-Black Patients
- First-line: Low-dose ACE inhibitor or ARB
- Second-line: Add DHP-CCB (like amlodipine)
- Amlodipine becomes appropriate as add-on therapy, not initial monotherapy 1
Black Patients
- First-line: Low-dose ARB + DHP-CCB (amlodipine) OR DHP-CCB + thiazide diuretic
- Amlodipine 5mg is appropriate as part of initial combination therapy 1
When Amlodipine Monotherapy IS Appropriate
Consider amlodipine 5mg as monotherapy in:
- Low-risk Grade 1 hypertension (140-159/90-99 mmHg) 1
- Patients aged >80 years 1
- Frail patients 1
- Black patients (though combination preferred) 1
Dosing Specifics from FDA Label
The FDA-approved starting dose is 5mg once daily for adults, with maximum 10mg daily 2. Small, fragile, or elderly patients may start at 2.5mg 2.
Critical timing: Wait 7-14 days between dose titrations, though more rapid titration is acceptable if clinically warranted with frequent assessment 2. However, research shows no advantage to early dose escalation—wait at least 6 weeks at 5mg before increasing to 10mg 3.
Efficacy Data
Amlodipine 5mg produces clinically significant BP reductions:
- Mean reduction: 12/6 mmHg (standing) and 13/7 mmHg (supine) 2
- 24-hour BP control maintained throughout dosing interval 4, 5, 6
- Response rate: 84% achieve DBP ≤90 mmHg 3
- Recent real-world data shows mean 24-hour SBP reduction of -20.2 mmHg with amlodipine 7
Common Pitfalls to Avoid
Don't start amlodipine as first-line in non-Black patients—this violates guideline recommendations that prioritize RASI therapy for cardiovascular and renal protection 1, 8
Don't uptitrate too quickly—the full antihypertensive effect takes 6 weeks to manifest 3. Early dose escalation provides no additional benefit.
Don't use amlodipine monotherapy in high-risk patients—those with CVD, CKD, diabetes, or organ damage should receive combination therapy immediately 1, 8
Don't forget the target—aim for BP <130/80 mmHg in most patients, achievable within 3 months 1, 8
Modern Guideline Context
The 2024 ESC guidelines recommend combination therapy as initial treatment for most patients with confirmed hypertension (BP ≥140/90 mmHg), preferably as single-pill combinations 8. The 2025 AHA/ACC guidelines similarly emphasize combination therapy for stage 2 hypertension 9. This represents a shift away from monotherapy approaches.
If you must use monotherapy: Amlodipine 5mg is reasonable in low-risk Grade 1 hypertension, elderly patients, or as part of bevacizumab-induced hypertension management 10, but recognize this is increasingly considered suboptimal for most newly diagnosed patients.